First Wave BioPharma announces final patient dosed in Phase 2 SPAN trial

First Wave BioPharma announced that the final patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. “Dosing the final patient is a key milestone in the Phase 2 SPAN clinical trial investigating our enhanced enteric microgranule delivery formulation of adrulipase for the treatment of EPI in CF patients,” said James Sapirstein, President and CEO of First Wave BioPharma. “We remain positioned to report topline data in July, which is expected to provide an initial indication of the new formulation’s ability to release adrulipase in the small intestine where the drug is designed to mix with food and deliver its therapeutic benefit. Ultimately our goal is to provide patients with a safe and effective therapy that allows individuals with CF to gain control over EPI, while diminishing the daily pill burden required with porcine-derived pancreatic enzyme replacement therapy.”